Lakefront Biotherapeutics has sold its early-stage CAR-T cell therapy programs to Armed Cell Therapeutics for an upfront payment of €8 million, with potential milestone payments up to $230 million and royalties. The programs, originally developed by AboundBio and acquired by Lakefront in 2022, focus on multi-targeting CAR-T constructs to enhance cancer treatment efficacy. This sale marks the near completion of Lakefront's wind-down of its legacy cell therapy activities, allowing Armed Cell Therapeutics to further develop these assets while Lakefront focuses on its new T-cell engager pipeline and maintains a strong cash position.
Lakefront Biotherapeutics' sale of preclinical CAR-T programs provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 15, 2026 00:42 WIB: out of 150 priced health-sector US stocks, 85 rose and 64 fell. Notable movers include CGC at USD 0.72 with a 1-day change of -5.57% and a typical hold time of 39 days, HIMS at USD 28.08 down 5.49% with a 21-day hold time, and CLPT at USD 9.32 down 4.94% with a 10-day hold time and 100% buy order activity.
Stephany Insurance LLC, a fourth-generation independent agency in Wexford, PA, is highlighted in a new 2026 guide for helping small businesses in Pittsburgh's North Hills identify and close insurance coverage gaps caused by rising premiums. The guide...
The Knowles-Rowland House, a $13.96 million redevelopment project by Bread of Life Inc., has opened in Midtown Houston, providing 31 permanent supportive housing units for individuals exiting chronic homelessness. The building, formerly a fire-damage...
ATLAS SP Partners, majority owned by Apollo funds, announced the pricing of $750 million senior notes due 2032 with a fixed 6.25% interest rate until November 2031, then switching to a floating rate based on SOFR plus a spread. The notes, issued by A...
Bending Spoons led market gainers with a 41.2% rise after Berkshire Hathaway increased its stake to 4% by investing an additional $330 million. Antelope Enterprise gained 36.4%, and NEXGEL rose 32.1% following a reverse stock split. Liquidia advanced...
The Law Offices of Frank R. Cruz is investigating Alignment Healthcare following a whistleblower lawsuit claiming the company misclassified $8-10 million in expenses to inflate its adjusted EBITDA and stock price. This alleged accounting manipulation...
